Curis, Inc. (CRIS)Healthcare | Biotechnology | Lexington, United States | NasdaqCM
0.60 USD
+0.01
(2.013%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 0.60 0.00 (-0.003%) ⇩ (April 17, 2026, 5:09 p.m. EDT) Short-term: ☆☆☆☆☆ | Long-term: ☆☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 11:39 p.m. EDT
CRIS presents a distressed failure scenario: deteriorating fundamentals (-66% revenue growth, negative gross/operating margins, -17% forecasted price action), eroding balance sheet (current ratio 0.49, negative FCF), and a "strong buy" recommendation based on inflated analyst price targets (mean 14.0 vs current 0.603) that do not reflect the near-term statistical reality. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.175184 |
| AutoETS | 0.197818 |
| AutoARIMA | 0.197872 |
| MSTL | 0.199443 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 59% |
| H-stat | 2.15 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.185 |
| Excess Kurtosis | -1.20 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 29.623 |
| Revenue per Share | 0.717 |
| Market Cap | 24,107,150 |
| Forward P/E | -0.63 |
| Beta | 3.14 |
| Profit Margins | -80.29% |
| Website | https://www.curis.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.53846157 |
| Address1 | Building C |
| Address2 | Suite 500 128 Spring Street |
| All Time High | 2,725.0 |
| All Time Low | 0.49 |
| Ask | 0.6245 |
| Ask Size | 5 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 1,256,770 |
| Average Daily Volume3 Month | 398,632 |
| Average Volume | 398,632 |
| Average Volume10Days | 1,256,770 |
| Beta | 3.136 |
| Bid | 0.5632 |
| Bid Size | 5 |
| Book Value | 0.422 |
| City | Lexington |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.603 |
| Current Ratio | 0.491 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 0.6722 |
| Day Low | 0.5831 |
| Debt To Equity | 29.623 |
| Display Name | Curis |
| Dividend Date | 1,527,638,400 |
| Earnings Call Timestamp End | 1,773,952,200 |
| Earnings Call Timestamp Start | 1,773,952,200 |
| Earnings Timestamp | 1,773,950,400 |
| Earnings Timestamp End | 1,778,011,200 |
| Earnings Timestamp Start | 1,778,011,200 |
| Ebitda | -32,733,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.631 |
| Enterprise To Revenue | 2.188 |
| Enterprise Value | 20,664,152 |
| Eps Current Year | -1.14667 |
| Eps Forward | -0.95667 |
| Eps Trailing Twelve Months | -0.58 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 0.85 |
| Fifty Day Average Change | -0.24700004 |
| Fifty Day Average Change Percent | -0.29058826 |
| Fifty Two Week Change Percent | -53.846157 |
| Fifty Two Week High | 3.13 |
| Fifty Two Week High Change | -2.5270002 |
| Fifty Two Week High Change Percent | -0.80734825 |
| Fifty Two Week Low | 0.49 |
| Fifty Two Week Low Change | 0.112999976 |
| Fifty Two Week Low Change Percent | 0.23061219 |
| Fifty Two Week Range | 0.49 - 3.13 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 965,136,600,000 |
| Float Shares | 30,891,136 |
| Forward Eps | -0.95667 |
| Forward P E | -0.63031137 |
| Free Cashflow | -10,457,375 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 20 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | -1.9968201 |
| Gross Profits | -18,856,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.02953 |
| Held Percent Institutions | 0.24952999 |
| Implied Shares Outstanding | 39,978,693 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ir Website | http://investors.curis.com/ |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,527,638,400 |
| Last Split Factor | 1:5 |
| Long Business Summary | Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small-molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreements with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed three programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts. |
| Long Name | Curis, Inc. |
| Market | us_market |
| Market Cap | 24,107,150 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_27159 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -7,582,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 24,107,151 |
| Number Of Analyst Opinions | 3 |
| Open | 0.6178 |
| Operating Cashflow | -27,201,000 |
| Operating Margins | -6.6520205 |
| Payout Ratio | 0.0 |
| Phone | 617 503 6500 |
| Post Market Change | -0.0029999614 |
| Post Market Change Percent | -0.49750605 |
| Post Market Price | 0.6 |
| Post Market Time | 1,776,460,168 |
| Previous Close | 0.5911 |
| Price Eps Current Year | -0.52587056 |
| Price Hint | 4 |
| Price To Book | 1.4289099 |
| Price To Sales Trailing12 Months | 2.5529122 |
| Profit Margins | -0.80292 |
| Quick Ratio | 0.36 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.25 |
| Region | US |
| Regular Market Change | 0.0119 |
| Regular Market Change Percent | 2.0132 |
| Regular Market Day High | 0.6722 |
| Regular Market Day Low | 0.5831 |
| Regular Market Day Range | 0.5831 - 0.6722 |
| Regular Market Open | 0.6178 |
| Regular Market Previous Close | 0.5911 |
| Regular Market Price | 0.603 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 1,139,558 |
| Return On Assets | -0.67168 |
| Revenue Growth | -0.66 |
| Revenue Per Share | 0.717 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 39,978,693 |
| Shares Percent Shares Out | 0.0016 |
| Shares Short | 62,944 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 652,145 |
| Short Name | Curis, Inc. |
| Short Percent Of Float | 0.0016 |
| Short Ratio | 0.26 |
| Source Interval | 15 |
| State | MA |
| Symbol | CRIS |
| Target High Price | 20.0 |
| Target Low Price | 5.0 |
| Target Mean Price | 14.0 |
| Target Median Price | 17.0 |
| Total Cash | 5,061,000 |
| Total Cash Per Share | 0.127 |
| Total Debt | 1,618,000 |
| Total Revenue | 9,443,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.58 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.29165 |
| Two Hundred Day Average Change | -0.6886501 |
| Two Hundred Day Average Change Percent | -0.5331553 |
| Type Disp | Equity |
| Volume | 1,139,558 |
| Website | https://www.curis.com |
| Zip | 2,421 |